Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer

Abstract

The association studies between miR-34b/c rs4938723 polymorphism and cancer risk showed conflicting results. This study aimed to assess the impact of rs4938723 polymorphism on prostate cancer risk. This case-control study was done on 151 prostate cancer (PCa) patients and 152 benign prostate hyperplasia to examine whether rs4938723 polymorphism in the promoter of pri-miR-34b/c was linked to the carcinogenesis of PCa in a sample of Iranian population. Genotyping of Pri-miR-34 b/c rs4938723 polymorphism was performed by using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. The results showed that rs4938723 variant significantly increased the risk of PCa in codominant (OR = 1.92, 95% CI = 1.15 - 3.18, p= 0.012, TC vs TT), dominant (OR = 1.99, 95% CI = 1.23 - 3.24, p= 0.005, TC + CC vs TT), and allelic (OR = 1.79, 95% CI = 1.20 - 2.68, p= 0.005, C vs T) inheritance model. Our findings propose that Pri-miR-34 b/c rs4938723 variant may be a risk factor for the development of PCa in a sample of Iranian population. Larger sample sizes with different ethnicities are required to validate our findings.

Association between genetic polymorphisms of long non‑coding RNA PRNCR1 and prostate cancer risk in a sample of the Iranian population

“…It has been suggested that lncRNA PRNCR1 promotes prostate carcinogenesis via activating AR (26). SNPs, a class of genetic variations, are commonly used in the prediction of cancer risk (38,44,45), prognosis (46) and clinical outcome (47). Cumulative evidence indicates that non-coding genes may be involved in gene expression complexity in humans (48,49).…”

“…In total, 358 subjects participated in this hospital-based case-control study, including 178 unrelated men with histopathologically confirmed prostate cancer and 180 age-matched unrelated men with benign prostatic hyperplasia (BPH), with no history of any type of cancer, as the control group (36)(37)(38)(39). All cases and controls were selected from a university-affiliated referral center (Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran).…”

Evaluation of a 3-base pair indel polymorphism within pre-microRNA-3131 in patients with prostate cancer using mismatch polymerase chain reaction-restriction fragment length polymorphism

“…Growing evidence has indicated that mutation or polymorphisms in miR genes could affect target-binding activity, expression or processes of mature miR, consequently affecting the expression of their target genes (15,16). Polymorphisms in miR have been demonstrated to be associated with the development of PCa (17,18,31,32). In present study, it was hypothesized that the 3-bp indel polymorphism of pre-miR-3131 may be associated with the development of PCa.…”

“…Mounting evidence has suggested that mutation or SNPs in miR genes may affect target-binding activity, expression, or processes of mature miR, thus affecting the expression of their target genes (15,16). Polymorphisms in mature and/or pre-miR sequences may affect miR biogenesis and be associated with the development of various types of cancer (17)(18)(19)(20)(21). Small insertions and deletion (indels) polymorphisms are one of the most common genetic alterations in the human genome that influence human traits and diseases (22,23).…”

“…To the best of our knowledge, for the first time, the present study aimed to determine the impact of a 3-bp indel polymorphism (rs57408770) within pre-miR-3131 on PCa susceptibility in a sample of an Iranian population. The study design and enrolment procedure were described previously (17,18,24). The project was approved by the local Ethics Committee of Zahedan University of Medical Sciences (Zahedan, Iran) and written informed consent was taken from all participants.…”